ABSTRACT
BACKGROUND: In oncology, pharmacists contribute to safety and effectiveness of drug treatment, identifying, preventing and forwarding solutions to drug-related problems (DRPs). However, it is still necessary to elucidate the profile of drug-related problems in pediatric cancer treatment to contribute to guide clinical pharmacy activities. METHODS: A retrospective cross-sectional study was conducted. Records on Excel® spreadsheets of 2 years of pharmaceutical assistance were analyzed regarding the prescriptions of chemotherapy for hospitalized patients aged 0-19 years. Data on age, sex, cancer diagnosis, protocol and drugs prescribed were collected. Causes and types of DRPs and pharmacists' interventions as their rate of acceptance were measured according to PCNE V 9.0. RESULTS: Drug-related problems were identified for 84 patients, in 5.3% of analyzed prescriptions. Leukemias, patients aged 0-4 years and male sex were associated with higher rates of drug-related problems. The BFM 2009 protocol for acute lymphocytic leukemia treatment had the highest frequency of prescriptions with drug-related problems. Main drug-related problems were related to effectiveness (49.2%) and safety (33.2%), with most of them due to drug selection and dose. Rate of acceptance of interventions was 92.2% and 90.6% of drug-related problems were fully resolved. Mercaptopurine and filgrastim were the drugs most associated with drug-related problems. Oral antineoplastic agents represented 36% of the prescriptions with drug-related problems. CONCLUSION: The high rate of acceptance of pharmacist interventions demonstrates the relevance of the pharmacist participation in the care of hospitalized pediatric patients undergoing chemotherapy. Pharmacists need to take attention to cases of necessity of drug prescription, intervening with other health professionals. Special attention to oral chemotherapy is required.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Pharmacy Service, Hospital , Humans , Male , Child , Pharmacists , Inpatients , Retrospective Studies , Drug Monitoring , Cross-Sectional Studies , Pharmacy Service, Hospital/methodsABSTRACT
BACKGROUND: Strategies to mitigate the impact of COVID-19 in special populations are complex and challenging. Few studies have addressed the impact of COVID-19 on pediatric patients with cancer in low- and middle-income countries. METHODS: Multicenter observational cohort study with prospective records and retrospective analyses starting in April 2020 in 21 pediatric oncology centers distributed throughout Brazil. PARTICIPANTS: Patients under 18 years of age who are infected by the SARS-CoV-2 virus (confirmed diagnosis through reverse transcriptase-polymerase chain reaction [RT-PCR]) while under treatment at pediatric oncology centers. The variables of interest included clinical symptoms, diagnostic and therapeutic measures. The repercussions of SARS-CoV-2 infection on cancer treatment and general prognosis were monitored. RESULTS: One hundred seventy-nine patients were included (median age 6 [4-13] years, 58% male). Of these, 55.9% had acute leukemia and 34.1% had solid tumors. The presence of SARS-CoV-2 was diagnosed by RT-PCR. Various laboratory markers were analyzed, but showed no correlation with outcome. Children with low or high BMI for age had lower overall survival (71.4% and 82.6%, respectively) than those with age-appropriate BMI (92.7%) (p = .007). The severity of presentation at diagnosis was significantly associated with outcome (p < .001). Overall mortality in the presence of infection was 12.3% (n = 22). CONCLUSION: In children with cancer and COVID-19, lower BMI was associated with worse prognosis. The mortality in this group of patients (12.3%) was significantly higher than that described in the pediatric population overall (â¼1%).
Subject(s)
COVID-19/complications , Neoplasms/complications , Adolescent , Body Mass Index , Brazil/epidemiology , COVID-19/epidemiology , Child , Child, Preschool , Female , Humans , Male , Neoplasms/epidemiology , Registries , Retrospective Studies , Risk Factors , SARS-CoV-2/isolation & purification , Survival AnalysisABSTRACT
RESUMEN Los tumores sólidos infantiles representan aproximadamente el 30% de todos los cánceres pediátricos. En los últimos años se ha incrementado el uso de la citometría de flujo (CF) en el diagnóstico y seguimiento de estas patologías, ya que es un método que permite obtener resultados rápidos y precisos, posibilitando un manejo más precoz. Realizamos esta revisión sistemática para la búsqueda bibliográfica de los siguientes términos en las plataformas de datos Lilacs, PubMed y Scielo: neoplasma, oncología, pediatría, inmunofenotipificación y citometría de flujo. Así, describimos los principales hallazgos hasta la fecha sobre el uso de CF en el diagnóstico diferencial de los cinco principales tumores de células pequeñas, redondas y azules de la infancia: neuroblastoma, sarcoma de Ewing, tumor neuroectodérmico primitivo, tumor de Wilms y rabdomiosarcoma. Además, describimos las principales ventajas y desventajas del método y paneles que se proponen en el diagnóstico diferencial de estas patologías a través de la literatura internacional. A través de esta revisión, observamos que el uso de CF en el diagnóstico de tumores sólidos puede ser útil para la identificación rápida y precisa de la efermedade, así como para el inicio más temprano del tratamiento.
ABSTRACT
An eight-year long case series follow-up study with pediatric bone cancer patients was conducted to compare the occurrence of adverse events associated with aprepitant with official sources of drug information (manufacturer's leaflet, clinical trials, and European Medicines Agency leaflet). All patients admitted were analyzed, representing 192 aprepitant cycles. Anorexia, febrile neutropenia, and headache were observed in frequencies over 43.8 per 100 patients, which was higher than previous estimates. Adverse events were classified as probable or possible, by using Naranjo score. The increased rates of adverse events, especially on the risk febrile neutropenia, warrant further safety studies on this population.
Subject(s)
Antiemetics/adverse effects , Aprepitant/adverse effects , Bone Neoplasms/drug therapy , Neurokinin-1 Receptor Antagonists/adverse effects , Child , Female , Humans , MaleABSTRACT
OBJECTIVES: To assess the association between estimated Mental Retardation (MR) and school dropout in a sample of students of the third and fourth grades at state schools in Porto Alegre, the capital of the southernmost state of Brazil. METHOD: In this case - control study, students that dropped out from schools (n=44) and a control group who continued attending schools (n=44) had their intelligence quotient (IQ) determined by the vocabulary and cubes subtests of the Wescheler Intelligence Scale ¾ third edition (WISC¾III). Students with IQ lower than 70 were considered as potential cases of MR. Other prevalent mental disorders in this age range were assessed in both groups using the Schedule for Affective Disorders and Schizophrenia for School¾ Age Children, Epidemiological Version (K-SADS-E). RESULTS: The prevalence of potential MR was significantly higher in the dropped out group than in the control group (p<0.001). Odds ratio for school dropout was significantly higher in the presence of MR even after controlling for potentially confounding factors (age, conduct disorder, grade repetition, family structure and income) (p<0.01). CONCLUSION: Children with IQ lower than 70 (potential MR) were at higher risk for school dropout. These children need to be identified at school and specific educational strategies should be implemented to assure their inclusion in the learning process